IP Library Granted Patent US 7,678,930
Granted Patent B2
US 7,678,930 · App. 10/520,897 · Granted Mar 16, 2010

Process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid

Assignee: Pronova Biopharma Norge AS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,678,930
App. No.
10/520,897
Granted
Mar 16, 2010
Kind
B2
Abstract

The invention relates to a process for decreasing the amount of cholesterol in a mixture comprising a marine oil, the marine oil containing the cholesterol, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide and a hydrocarbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of cholesterol present in the marine oil in free form is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile cholesterol decreasing working fluid and a health supplement and a pharmaceutical, based on a marine oil, prepared according to the process mentioned above.

Claims (31)

1. A process for decreasing the concentration of cholesterol in a marine oil in a pharmaceutical composition, the marine oil comprising cholesterol in free form, said process comprising:

a) adding a volatile working fluid to the marine oil, wherein the volatile working fluid comprises at least one fluid chosen from fatty acid esters, fatty acid amides, and hydrocarbons, and

b) subjecting the mixture of marine oil and volatile working fluid from step (a) to at least one stripping processing step, wherein an amount of the cholesterol present in the marine oil in free form is separated from the mixture together with the volatile working fluid; and

wherein said pharmaceutical composition is not a health supplement.

2. The process according to claim 1 , wherein the volatile working fluid is essentially equally or less volatile than the cholesterol in free form that is to be separated from the marine oil mixture.

3. The process according to claim 1 , wherein the fatty acid moieties of said fatty acid esters and fatty acid amides are obtained from a fat or oil obtained from at least one of vegetable, microbial, and animal origins.

4. The process according to claim 3 , wherein the animal fat or oil is a marine oil.

5. The process according to claim 1 , wherein the volatile working fluid comprises at least one fatty acid ester composed of a C10-C22 fatty acid esterified with a C1-C4 alcohol.

6. The process according to claim 1 , wherein the marine oil comprises at least one fatty acid chosen from saturated fatty acids in the form of triglycerides and unsaturated fatty acids in the form of triglycerides, and wherein the marine oil is obtained from fish or sea mammals.

7. The process according to claim 1 , wherein the ratio of (volatile working fluid) (marine oil) ranges from about 1:100 to 15:100.

8. The process according to claim 7 , wherein the ratio of (volatile working fluid):(marine oil) ranges from about 3:100 to 8:100.

9. The process according to claim 1 , wherein said at least one stripping processing step is carried out at a temperature in the range of 120-270° C.

10. The process according to claim 1 , wherein said at least one stripping processing step is carried out at a temperature in the range of 150-220° C.

11. The process according to claim 1 , wherein said at least one stripping processing step is carried out at a pressure below 14 mbar.

12. The process according to claim 1 , wherein said at least one stripping processing step is chosen from thin-film evaporation processes, molecular distillations, short-path distillations, and any combinations thereof.

13. The process according to claim 12 , wherein the thin-film evaporation process is carried out at a mixture flow rate in the range of 30-150 kg/h·m 2 .

14. The process according to claim 1 , wherein said at least one stripping processing step is carried out at a mixture flow rate in the range of 80-150 kg/h·m 2 .

15. The process according to claim 1 , wherein the volatile working fluid is a distillate fraction from a process in which a mixture comprising at least one of ethyl and methyl esters of fatty acids obtained from marine oil is fractionated by distillation.

16. The process according to claim 1 wherein the marine oil further comprises cholesterol in bound form, and wherein the at least one stripping processing step is followed by the steps:

c) subjecting the stripped marine oil to at least one trans-esterification reaction with a C 1 -C 6 alcohol under substantially anhydrous conditions; and

d) subjecting the transesterified marine oil from step (c) to at least one distillation procedure that yields a distillate marine oil fraction and a residue marine oil fraction, wherein the distillate marine oil fraction has concentrations of free and bound cholesterol lower than in the residue fraction.

17. The process according to claim 16 , wherein said C 1 -C 6 alcohol is ethanol.

18. A process for decreasing the concentration of cholesterol in a marine oil comprising cholesterol in free form comprising:

a) adding a volatile working fluid to the marine oil, wherein the volatile working fluid comprises at least one fluid chosen from fatty acid esters, fatty acid amides, and hydrocarbons, and

b) subjecting the mixture of marine oil and volatile working fluid from step (a) to at least one stripping processing step, wherein an amount of the cholesterol present in the marine oil in free form is separated from the mixture together with the volatile working fluid;

wherein said process decreases the concentration of cholesterol in free form in the pharmaceutical composition to 1.4 mg/g to 3 mg/g.

19. The process according to claim 18 , wherein the volatile working fluid is essentially equally or less volatile than the cholesterol in free form that is to be separated from the marine oil mixture.

20. The process according to claim 18 , wherein the fatty acid moieties of said fatty acid esters and fatty acid amides are obtained from a fat or oil obtained from at least one of vegetable, microbial, and animal origins.

21. The process according to claim 20 , wherein the animal fat or oil is a marine oil.

22. The process according to claim 18 , wherein the volatile working fluid comprises at least one fatty acid ester composed of a C10-C22 fatty acid esterified with a C1-C4 alcohol.

23. The process according to claim 18 , wherein the marine oil comprises at least one fatty acid chosen from saturated fatty acids in the form of triglycerides and unsaturated fatty acids in the form of triglycerides, and wherein the marine oil is obtained from fish or sea mammals.

Assignments (2)
CHANGE OF NAME Recorded Sep 10, 2007
From: PRONOVA BIOCARE A/S
To: PRONOVA BIOPHARMA NORGE AS
Reel/Frame 019795/0594 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2005
From: SONDBO, SVERRE; THORSTAD, OLAV
To: PRONOVA BIOCARE AS
Reel/Frame 016801/0810 →
Priority Claims (2)
SE 0202188 · Jul 11, 2002 · national
WO PCT/IB/03/02827 · Jul 8, 2003 · international
Continuity (1)
Related Publication 20060134303A1 · Jun 22, 2006